Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 16/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1467078 | 1.00 | LRRK2 (0.51) | LRRK2PTK2TTKALK | |
| SCHEMBL1466613 | 0.91 | LRRK2 (0.51) | LRRK2PTK2TTK | |
| SCHEMBL12745482 | 0.91 | LRRK2 (0.51) | LRRK2PTK2TTK | |
| SCHEMBL1466652 | 0.88 | LRRK2 (0.59) | LRRK2PTK2TTKALK | |
| SCHEMBL12745494 | 0.88 | LRRK2 (0.59) | LRRK2PTK2TTKALK | |
| SCHEMBL12826845 | 0.85 | LRRK2 (0.62) | LRRK2PTK2ALK | |
| SCHEMBL12826698 | 0.85 | LRRK2 (0.62) | LRRK2PTK2TTK | |
| SCHEMBL12745497 | 0.84 | LRRK2 (0.60) | LRRK2PTK2TTKALK | |
| SCHEMBL1466072 | 0.84 | LRRK2 (0.60) | LRRK2PTK2TTKALK | |
| SCHEMBL12826691 | 0.84 | LRRK2 (0.59) | LRRK2PTK2TTKALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408752-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-08-12 | — | — | EP | disclosed |
| US-20140051674-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| US-20140051674-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| US-20110071158-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071158-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| WO-2010106097-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051674-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | LRRK2 1540/4885PTK2 1621/4885TTK 4656/4885 |
| US-20110071158-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | LRRK2 1540/4885PTK2 1621/4885TTK 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.